Preclinical studies have suggested a direct connection between the AKT which is a target for many anti-cancer agents [9] and AR signaling cascade, showing a dynamic interplay between these pathways during the development of ADT resistance and the development of androgen insensitivity. The gene discussed is AR; the disease is cancer.